32P-磷酸铬-聚 L-乳酸缓释粒子的制备及其放射性释出和生物分布

Objective The aim of this study was to prepare the 32P-chromic phosphate-poly(L-lac-tide) (32P-CP-PLLA) particles with different ratio of the materials and further examine their performance in-dex in vivo and in vitro and their intracorporeal distribution. Methods The erosion, degrading rates, de-layed release velocity and radioactivity self-absorption coefficient (RSAC) of 32P-CP-PLLA particles made from different materials were investigated and compared. After the implantation of 32P-CP-PLLA particles and the injection of 32P-CP colloids in the muscular tissues, the weight loss rate and the radioactivity release rate (RRR) of the particles were calculated. The intracorporeal distribution, radioactive half-life and bio-logical effect of 32P in the targeting sites were further studied. Statistical analysis was performed with SPSS 12.0, and one-way analysis of variance and t-test were used. Results 32P-CP-PLLA particles were of green cylinder, with regular shape and radionuclide distribution. The RSAC of the particles was of little re-lation with molecular weight of PLLA and proportional to the ratio of PLLA to CP. The extracorporeal release rate increased with the reduction of molecular weight of PLLA and with the increase of the ratio of PLLA to CP. The RRR reached peak when PLLA was 3 times of CP. The 32P-CP, released with the degradation and corrosion of the particle distributed mainly in the surrounding muscles of the particle. And the peak of per-centage activity of injection dose per gram of tissue (% ID/g) in liver, spleen and bone were 1. 7887, 1. 6401 and 1. 9470 respectively, much lower than that in the 32P-CP group (4.7523, 3.9712 and 4.3174 ; all t > 2.7, all P < 0.05). The % ID/g in other organs was much less. The radioactivity effective half-life in the targeting sites increased to about 13 d. There was widespread necrosis around the particles with no ex-istence of normal tissues among them. And no abnormality in spleen and liver was found. Conclusion As a better dosage form of pure β-particle emitter, 32P-CP-PLLA, which can increase the targeting radioactive dosage and effective half-life in the implanting sites, can be served as an potential implanting agent for onco-therapy with a better perspective.     

~(32)P-磷酸铬-聚L-乳酸粒子植入实验鼠体内降解特性及代谢

目的 观察~(32)P-磷酸铬-聚L-乳酸(~(32)P-CP-PLLA)粒子植入实验鼠体内的降解特性及代谢.方法 KM小鼠72只,采用开腹或经皮穿刺法将~(32)P-CP-PLLA粒子分别植入小鼠肝、腹腔及腿部肌肉,粒子植入前活度为20.44～25.14 kBq,30 d内不同时间处死,取出粒子,取血及主要脏器测~(32)P放射性计数率,计算每克组织的百分剂量率(%ID/g),用扫描电镜动态观察粒子形态变化.SD大鼠5只,肝内植入粒子后代谢笼饲养,每24小时测量粪便及尿液放射性,计算~(32)P30 d排泄率.计量数据以-x±s表示,采用SPSS 13.0软件进行统计分析.结果 KM小鼠体内生物分布显示~(32)P-CP-PLLA 粒子植入后无一发生粒子移位,释出的~(32)PP在重要脏器和组织中放射性分布略高于本底水平.30 d内组织脏器计数率之和呈现阶段性变化:肝组1～5 d各脏器摄取总值极少,6～10 d略增多,11～20 d又趋减少,21～25 d摄取再次增多,达到峰值(622±11)计数/min,26-30 d略有下降;肌肉组变化与肝组相似,唯峰时提前(15 d),且峰值相对较低,为(403±14)计数/min;腹腔组重要脏器摄取呈持续低水平,无明显阶段性变化.粪便和尿液放射性峰值分别出现在第16天和第19天,排泄率分别为(0.82±0.20)%和(0.50±0.23)%,30 d总排泄率分别为4.08%和1.33%.结论 ~(32)P-CP-PLLA粒子作为一种新型治疗恶性肿瘤植入剂,在体内无脏器迁移,粒子呈现阶段性缓慢降解,降解物不具胶体特性,较少通过粪便和尿液排出体外,显示出良好的体内稳定性、靶向定位性和安全性.     

宋府金丹酒抑制关节炎症的实验研究

目的：研究宋府金丹酒对关节炎症的抑制作用。方法：观察宋府金丹酒对大鼠佐剂性关节炎和甲醛致炎大鼠足跖肿胀的影响。结果：宋府金丹酒对佐剂性关节炎大鼠续发性病变有较好的预防和治疗作用,对甲醛致大鼠足跖炎症有较好的抑制作用。结论：宋府金丹酒能有效抑制关节炎症。     

盐酸去甲乌药碱负荷心肌灌注显像与负荷心电图对冠心病诊断价值的对比研究

目的：比较盐酸去甲乌药碱（HG）负荷心肌灌注显像（MPI）和负荷心电图（ECG）对冠心病的诊断价值。方法70例患者同时完成HG负荷核素MPI及冠脉造影（CAG）检查,在心肌灌注负荷试验过程中观察ECG变化,并与同期负荷MPI和冠脉造影结果作对比。结果以CAG结果为金标准,HG负荷MPI诊断冠心病的敏感性、特异性、阳性预测值、阴性预测值、准确性分别为55.8%、92.6%、92.3%、56.8%、70%,HG负荷ECG诊断冠心病的敏感性、特异性、阳性预测值、阴性预测值、准确性分别为74.4%、29.6%、62.7%、42.1%、57.1%。MPI的特异性和阳性预测值明显高于ECG（P＜0.01）,敏感性、阴性预测值、准确性两者统计学差异不大（P＞0.05）。结论 HG可作为负荷MPI和负荷ECG药物来诊断冠心病,且HG负荷MPI的特异性要优于HG负荷ECG。     

络病理论在肾病中的应用

络病学说是指导内伤疑难杂病临床治疗的应用理论,掌握络病发病特点、病理变化、临床特征及治疗方药将会使许多病程较长、反复发作的难治性疾病的临床治疗取得新的突破,着重阐述了应用络病理论在诊治慢性肾功能衰竭中具有重要现实意义.     

抗甲状腺球蛋白抗体和18F-FDG符合线路显像在分化型甲状腺癌随访中的临床应用

目的 探讨分化型甲状腺癌(DTC)手术和131Ⅰ治疗后,血清甲状腺球蛋白(Tg)水平阴性时,血清抗甲状腺球蛋白抗体(TgAb)是否可以反映DTC的复发和转移以及18F-FDG SPECT符合线路显像对这些患者的诊断灵敏度和临床随访价值.方法 对52例临床经手术和131Ⅰ清除残余甲状腺治疗后的DTC患者随访发现11例患者(21.15%)的血清TgAb浓度均为阳性(＞40 IU/ml,范围为84.0～5450.0 IU/ml),但血清Tg＜0.2 ng/ml;随访期间行18F-FDG SPECT符合线路显像和131 Ⅰ全身显像,计算其诊断复发转移灶的灵敏度、特异性,必要时行全身骨显像、X/CT、B超、MRI检查等.结果 11例血清TgAb浓度均为阳性的患者中18F-FDG SPECT符合线路显像和131Ⅰ全身显像共发现8例患者阳性病灶13个,18F-FDG SPECT符合线路显像发现阳性病灶8个,其中纵膈转移2个,颈部病灶(包括残留病灶和颈淋巴结转移)6个,阴性病灶5个(假阴性),其中颈淋巴结转移3个,纵膈和肺转移各1个,18F-FDG SPECT符合线路显像的灵敏度61.5%,特异性100%,阳性预期值100%;131Ⅰ全身显像发现阳性病灶10个,其中纵隔转移2个,肺转移1个,颈部病灶(包括残留病灶和颈淋巴结转移)7个,阴性病灶3个(假阴性),其中纵隔转移1个,颈淋巴结转移2个,131Ⅰ全身显像灵敏度76.92%,特异性lOO%,阳性预期值90.9%.结论 当DTC患者上血清Tg处于低水平状态时,如果TgAb水平持续升高,可以作为诊断DTC转移或复发的一个有价值的肿瘤标志物.18F-FDG SPECT符合线路显像对DTC复发和转移较敏感,可用于血清TgAb浓度升高而Tg水平阴性时的DTC复发和转移的监测.     

心肌缺血程度与ET-1、TXB2、6-keto-PGF1α水平相关性分析

为了解不同缺血程度冠心病（CHD）患者血浆中内皮素-1（ET-1）和血栓素B2（TXB2）、6-酮-前列腺素F1α（6-keto—PGF1α）水平,现经检测后将结果报道如下。     

32P-磷酸铬-聚 L-乳酸缓释粒子的制备及其放射性释出和生物分布

Objective The aim of this study was to prepare the 32P-chromic phosphate-poly(L-lac-tide) (32P-CP-PLLA) particles with different ratio of the materials and further examine their performance in-dex in vivo and in vitro and their intracorporeal distribution. Methods The erosion, degrading rates, de-layed release velocity and radioactivity self-absorption coefficient (RSAC) of 32P-CP-PLLA particles made from different materials were investigated and compared. After the implantation of 32P-CP-PLLA particles and the injection of 32P-CP colloids in the muscular tissues, the weight loss rate and the radioactivity release rate (RRR) of the particles were calculated. The intracorporeal distribution, radioactive half-life and bio-logical effect of 32P in the targeting sites were further studied. Statistical analysis was performed with SPSS 12.0, and one-way analysis of variance and t-test were used. Results 32P-CP-PLLA particles were of green cylinder, with regular shape and radionuclide distribution. The RSAC of the particles was of little re-lation with molecular weight of PLLA and proportional to the ratio of PLLA to CP. The extracorporeal release rate increased with the reduction of molecular weight of PLLA and with the increase of the ratio of PLLA to CP. The RRR reached peak when PLLA was 3 times of CP. The 32P-CP, released with the degradation and corrosion of the particle distributed mainly in the surrounding muscles of the particle. And the peak of per-centage activity of injection dose per gram of tissue (% ID/g) in liver, spleen and bone were 1. 7887, 1. 6401 and 1. 9470 respectively, much lower than that in the 32P-CP group (4.7523, 3.9712 and 4.3174 ; all t > 2.7, all P < 0.05). The % ID/g in other organs was much less. The radioactivity effective half-life in the targeting sites increased to about 13 d. There was widespread necrosis around the particles with no ex-istence of normal tissues among them. And no abnormality in spleen and liver was found. Conclusion As a better dosage form of pure β-particle emitter, 32P-CP-PLLA, which can increase the targeting radioactive dosage and effective half-life in the implanting sites, can be served as an potential implanting agent for onco-therapy with a better perspective.     

护牙宝对变异链球菌的抑制作用研究

目的:研究护牙宝慕斯对由变异链球菌(S. Mutans)引起的龋病的预防作用。方法:以护牙宝慕斯为对象,采用牛津被法测定护牙宝对S. Mutans的抑制作用,并采用二倍稀释法测定其最低抑菌浓度(MIC)。结果:护牙宝原液以及稀释液均对S. Mutans表现出较好的抑制效果,其原液抑菌圈可达(22. 5±0. 5) mm,8%护牙宝稀释液抑菌圈为(17. 7±0. 7) mm。采用二倍稀释法测定其MIC为1%护牙宝原液浓度。结论:即使经过口腔稀释,护牙宝也能起到预防由S. Mutans引起的龋病的作用。